Upfront radiotherapy tied to better outcomes for brain metastases in EGFR-Mutant NSCLC

Stereotactic radiosurgery followed by treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor appears to provide the best survival for patients with brain metastases from EGFR-mutant non-small-cell lung cancer (NSCLC), according to new findings.
Medscape